BEIJING, Sept. 4 Sinovac Biotech Ltd. (NYSE: SVA), aleading provider of biopharmaceutical products in China, announced today thatthe Ministry of Industry and Information Technology of the People's Republicof China has issued the initial order to Sinovac to purchase H1N1 vaccine forthe national stockpiling plan. According to the initial order, Sinovac isrequired to complete the production of 3.3 million doses of PANFLU.1(15ug/0.5ml), the H1N1 vaccine manufactured by Sinovac, before September 15,2009. Two doses of the vaccine are packaged in one vial.
Sinovac initiated the production of H1N1 vaccine on June 15, 2009 andinitiated the clinical trial on July 22. On August 17, Sinovac announced itstop-line positive results of H1N1 vaccine clinical trials, in which thevaccine showed good safety and immunogenicity profiles after one shot.Following the positive results of an experts' evaluation conference organizedby the State Food and Drug Administration (SFDA), on September 3, 2009,Sinovac obtained the production license from the SFDA for PANFLU.1, Sinovac'sH1N1 vaccine.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,"Sinovac has been aiming to provide Chinese children with international-quality vaccines and provide children throughout the world with vaccines madein China, and to fulfill our mission of supplying vaccines to eliminate humandiseases. Sinovac is very glad to be supplying our H1N1 vaccine to the Chinesegovernment and we are confident that we can complete the national H1N1 vaccinestockpiling task in a timely manner."
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac's vaccineproducts include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A andB), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine(H5N1), has already been approved for government stockpiling. Sinovac isdeveloping vaccines for enterovirus 71, universal pandemic influenza, Japaneseencephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, isconducting field trials for independently developed inactivated animal rabiesvaccines.
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that are nothistorical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update anyforward-looking statement, except as required under applicable law.For more information, please contact: Sinovac Biotech Ltd.: Helen G. Yang Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: [email protected]
Investors: Amy Glynn/Sara Pellegrino The Ruth Group Tel: +1-646-536-7023/7002 Email: [email protected] [email protected]
Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033 Email: [email protected]
SOURCE Sinovac Biotech Ltd.